Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume -, Issue -, Pages annrheumdis-2021-221490
Publisher
BMJ
Online
2022-01-01
DOI
10.1136/annrheumdis-2021-221490
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Myanmar's health leaders stand against military rule
- (2021) Zaw Wai Soe et al. LANCET
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
- (2021) Noa Dagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
- (2021) Nikolaos C. Kyriakidis et al. npj Vaccines
- SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
- (2021) David Simon et al. ANNALS OF THE RHEUMATIC DISEASES
- Response to: ‘Correspondence on ‘EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs’’ by Bugatti et al
- (2021) Johannes W J Bijlsma ANNALS OF THE RHEUMATIC DISEASES
- Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
- (2021) Eleftheria Vasileiou et al. LANCET
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
- (2021) Eric J Haas et al. LANCET
- Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
- (2021) Ian McDonald et al. npj Vaccines
- Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
- (2021) Claire Cook et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0546 5 YEARS FOLLOW-UP OF PSORIATIC ARTHRITIS PATIENTS TREATED ACCORDING TREAT-TO-TARGET STRATEGY. PRELIMINARY RESULTS
- (2021) P. Tremaskina et al. ANNALS OF THE RHEUMATIC DISEASES
- Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
- (2021) Giuseppe A Ramirez et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
- (2021) Victoria Furer et al. ANNALS OF THE RHEUMATIC DISEASES
- Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City
- (2021) Medha Barbhaiya et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0146 HAND AND WRIST ACTIVE RANGE OF MOTIONS AND CONTRIBUTING FACTORS IN RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY
- (2021) M. He et al. ANNALS OF THE RHEUMATIC DISEASES
- Evaluation of the safety profile of COVID-19 vaccines: a rapid review
- (2021) Qianhui Wu et al. BMC Medicine
- Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
- (2021) Ana C. Medeiros-Ribeiro et al. NATURE MEDICINE
- Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
- (2021) Somy Cherian et al. RHEUMATOLOGY INTERNATIONAL
- Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis
- (2021) Lars Erik Bartels et al. RHEUMATOLOGY INTERNATIONAL
- Evaluation of Immune Response and Disease Status in SLE Patients Following SARS‐CoV‐2 Vaccination
- (2021) Peter M. Izmirly et al. Arthritis & Rheumatology
- ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
- (2021) Andrea Picchianti-Diamanti et al. Frontiers in Immunology
- Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study
- (2021) Cinzia Rotondo et al. Vaccines
- Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
- (2021) Sebastian Eduardo Sattui et al. RMD Open
- Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
- (2021) Renaud Felten et al. Lancet Rheumatology
- BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus
- (2021) Quentin Moyon et al. ANNALS OF THE RHEUMATIC DISEASES
- Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study
- (2021) Jorge Antonio Esquivel-Valerio et al. RHEUMATOLOGY INTERNATIONAL
- The REDCap consortium: Building an international community of software platform partners
- (2019) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
- Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study
- (2017) Shafay Raheel et al. RHEUMATOLOGY
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
- (2008) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started